Navigation Links
Uptake Medical® Expands Executive Team, Announces European General Manager Lloyd Mencinger
Date:9/6/2011

TUSTIN, Calif., Sept. 6, 2011 /PRNewswire/ -- Uptake Medical® Corp., maker of InterVapor™, a minimally invasive treatment for severe emphysema, today announced that seasoned medical device executive Lloyd Mencinger has joined the company as European General Manager, effective September 1, 2011.

Mr. Mencinger joins Uptake Medical with nearly three decades of broad functional experience with medical device leaders such as Boston Scientific, Baxter, and American Hospital Supply and most recently with Tenent Healthcare serving as Senior Vice President of Business Development, providing him with insights into the evolving healthcare environment. His tenure with Boston Scientific included nearly 10 years living within the European Union focusing on sales, marketing, business development, operations and clinical economics & government affairs.

"It is rare to find such broad functional expertise in one individual. We are thrilled to welcome Lloyd to Uptake Medical," said King Nelson, President and CEO. "Specifically, Lloyd's extensive experience in building markets for innovative technologies, his understanding of global healthcare environments and his ability to navigate appropriate channels to secure reimbursement will be major assets as we move towards commercialization."

InterVapor is the first and only personalized endoscopic lung volume reduction procedure to use the energy of heated water vapor and the body's own healing process to target hyperinflation. With InterVapor, the diseased lung volume is reduced, giving patients with severe emphysema clinically meaningful improvement in breathing function and quality of life. This is done without implants or chemicals being placed or left behind in the delicate lung tissue.

About his appointment, Mr. Mencinger commented, "The global burden of emphysema is large and growing, and the opportunity to introduce a unique technology, such as InterVapor, to help this population of patients is truly exciting. Uptake Medical's pioneering approach to lung volume reduction is certain to help improve the quality of life for many emphysema sufferers."

About Emphysema:

Emphysema and chronic bronchitis are captured under the umbrella of Chronic Obstructive Pulmonary Disease (COPD). The Word Health Organization has stated that the incidence of COPD is on the rise, on pace to becoming the third leading cause of death by 2030. In the United States, where nearly 5 million people are diagnosed with emphysema, it already holds this position, with one person dying every 4 minutes. Debilitating and costly, nearly $50 billion was spent on the direct and indirect costs associated with COPD in the U.S. in 2010.

About Uptake Medical:

With headquarters in Tustin, Calif., Uptake Medical develops innovative medical technologies for the treatment of lung diseases. Its first product, InterVapor, is the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body's natural healing process without leaving any foreign materials in the lung. In clinical studies, InterVapor has demonstrated clinically meaningful improvements in breathing function, exercise capacity and quality of life. More information can be found at www.uptakemedical.com.

Uptake Medical and InterVapor are registered trademarks and trademarks of Uptake Medical.


'/>"/>
SOURCE Uptake Medical Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Opioids Market to 2017 - Steady Uptake of Oxycontin and High Incidence Of Diseases Such As Cancer And Arthritis to Drive the Market
2. Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions
3. Uptake Medical Announces Scott Huennekens Elected to Board of Directors
4. The Harley Medical Group Sees an Uptake in Surgery Bookings for Christmas
5. Uptake Medical Names J.C. MacRae as Chief Financial Officer
6. Driven by the Uptake of Several Emerging Agents, the MRSA Drug Market Will Increase From $631 Million in 2009 to $752 Million in 2019
7. Introduction of New Products and Increased Uptake of Innovative Materials to Drive US Bone Graft Substitute Market to Nearly $2.3 Billion by 2015
8. The Continued Uptake of Key Agents Such as Januvia, Bydureon and Byetta Will Drive The Type 2 Diabetes Drug Market to Nearly Double From $19 Billion in 2009 to $36 Billion in 2019
9. BridgePoint Medical®, Inc. Completes and Submits to FDA in the U.S. FAST-CTOs With the CrossBoss® and Stingray® CTO Recanalization System
10. Pacira Pharmaceuticals, Inc. Expands EXPAREL™ Commercial Team Infrastructure
11. IRIDEX Expands ENT Laser Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... NASHVILLE , Tenn. and DALLAS , ... and EndoStim, Inc., announced that the first patients in ... with the EndoStim device in the Lower Esophageal Sphincter ... is a minimally-invasive implantable device designed to provide long-term ... through neurostimulation. GERD affects nearly 65 million ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-naïve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
(Date:4/18/2017)... April 18, 2017 Research and Markets has ... report to their offering. ... The global arthroscopy devices market to grow at a CAGR of ... Arthroscopy Devices Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
Breaking Medicine Technology:
(Date:4/28/2017)... Edinburg, Texas (PRWEB) , ... April 28, 2017 , ... ... a plaque in recently to the labor and delivery team at Women’s Hospital at ... generous mothers who give birth at the hospital and decide to donate. , ...
(Date:4/28/2017)... ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh ... Creator responds to and which He does not. Yisrayl says with so many titles ... the true name, but he says with a little Scripture, backed with a lot of ...
(Date:4/28/2017)... ... 28, 2017 , ... NuevaCare, a leading home care agency based in San ... Alto, is proud to announce information upgrades to its blog in the form of ... on topics such as home care (generally) as well as senior care and home ...
(Date:4/27/2017)... ... 2017 , ... The Incentive Research Foundation is pleased to ... a groundbreaking analysis of how behavioral economics can be applied to the incentive, ... programs, the report highlights proven behavioral economics approaches and the powerful role emotions ...
(Date:4/27/2017)... ... April 27, 2017 , ... SyncDog, Inc. ... at MobileIron Live! 2017 in Santa Clara, California. Each year, MobileIron ... approach to helping organizations maximize the benefits of mobility in their operations securely. ...
Breaking Medicine News(10 mins):